F. Quirini

发表

Extranodal marginal zone B‐cell lymphoma of the lung: experience with fludarabine and mitoxantrone‐containing regimens

S. Pileri, M. Baccarani, V. Poletti, 2013, Hematological oncology.

A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma.

S. Pileri, M. Baccarani, S. Fanti, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified

S. Pileri, M. Baccarani, P. Zinzani, 2011, Leukemia & lymphoma.

Hairy cell leukemia

S. Pileri, M. Baccarani, P. Zinzani, 2010, Cancer.

Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study

M. Baccarani, V. Pavone, P. Zinzani, 2013, Hematological oncology.

Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.

S. Pileri, M. Baccarani, P. Zinzani, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Primary bone lymphoma: evaluation of chemoimmunotherapy as front-line treatment in 21 patients.

S. Pileri, M. Baccarani, P. Zinzani, 2011, Clinical lymphoma, myeloma & leukemia.

Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients

M. Baccarani, P. Zinzani, E. Derenzini, 2013, Leukemia & lymphoma.

Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial.

S. Pileri, M. Baccarani, P. Zinzani, 2011, Clinical lymphoma, myeloma & leukemia.

The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients

P. Zinzani, A. Broccoli, V. Stefoni, 2017, BMC Cancer.

90‐yttrium‐ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high‐risk follicular lymphoma: updated long‐term results after a median follow‐up of 7 years

P. Zinzani, A. Pulsoni, A. De Renzo, 2016, Cancer medicine.

Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients

P. Zinzani, E. Derenzini, M. Ladetto, 2015 .

Midtreatment 18F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma

M. Baccarani, S. Fanti, P. Zinzani, 2011, Cancer.

The Role of Interim-PET and Final-PET in the Outcome of Peripheral T-Cell Lymphoma (PTCL) Treated At the Diagnosis with CHOP.

P. Zinzani, E. Derenzini, A. Broccoli, 2012 .

The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients

P. Zinzani, A. Broccoli, V. Stefoni, 2017, BMC Cancer.

High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience

P. Zinzani, E. Derenzini, A. Broccoli, 2015, BMC Cancer.

A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma.

S. Pileri, M. Baccarani, S. Fanti, 2012, Annals of Oncology.

Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.

S. Pileri, M. Baccarani, P. Zinzani, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.